UK Markets closed
NIKKEI 225
26,739.03 +336.19 (+1.27%) HANG SENG
20,717.24 +596.56 (+2.96%) CRUDE OIL
110.35 +0.46 (+0.42%) GOLD FUTURES
1,845.10 +3.90 (+0.21%) DOW
31,261.90 +8.77 (+0.03%) BTC-GBP
23,372.98 -980.96 (-4.03%)
Regeneron Pharmaceuticals, Inc. (REGN)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 04:00PM EDT. Market open.
| Previous close | 657.15 |
| Open | 661.29 |
| Bid | 645.63 x 800 |
| Ask | 662.89 x 800 |
| Day's range | 647.54 - 664.85 |
| 52-week range | 492.13 - 747.42 |
| Volume | |
| Avg. volume | 646,824 |
| Market cap | 71.101B |
| Beta (5Y monthly) | 0.21 |
| PE ratio (TTM) | 10.57 |
| EPS (TTM) | 62.53 |
| Earnings date | 03 Feb 2022 - 07 Feb 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 702.05 |
- Zacks
Regeneron's (REGN) Evkeeza Positive in Late-Stage Study
Regeneron (REGN) announces positive data on a phase III study on cholesterol treatment Evkeeza.
- Zacks
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.
- Zacks
The Zacks Analyst Blog Highlights Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven Pharmaceutical
Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven Pharmaceutical are part of Zacks top Analyst Blog
© 2022 Yahoo. All rights reserved.
